Genpharm is proud to announce the appointment of Mr. Mark Rothera to the company’s executive board.

Mark joins the board, having spent more than 20 years of his 30 year BioPharma career, bringing innovative treatments to patients with rare diseases globally. He most recently served as CEO of Orchard Therapeutics, a leading gene therapy company and was previously chief commercial officer of PTC Therapeutics. Mark previously served on the board of the Alliance for Regenerative Medicines (ARM) in the US.

“We are honored to have Mark on our Board to support Genpharm’s mission. His long standing experience in launching therapies for rare diseases, his in-depth knowledge of Gene therapy and his established network will help Genpharm consolidate its leadership position in the Middle East North African (MENA) region”, noted Genpharm’s managing partners Karim Smaira and Kamel Ghammachi. 

“I am delighted to join Genpharm’s board. As a passionate advocate of the need for novel treatments for patient communities living with rare or specialized diseases around the world, I have seen first-hand the difference that the Genpharm team are making for patients suffering life-limiting, devastating diseases in the Middle East, North African region. I look forward to helping them bring the latest innovations to patients in the region”, noted Mark Rothera.